5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICA-riboside) as a targeting agent for therapy of patients with acute lymphoblastic leukemia: are we there and are there pitfalls?

J Pediatr Hematol Oncol. 2007 Dec;29(12):805-7. doi: 10.1097/MPH.0b013e31815bbb83.
No abstract available

MeSH terms

  • Aminoimidazole Carboxamide / analogs & derivatives*
  • Aminoimidazole Carboxamide / therapeutic use
  • Aminoimidazole Carboxamide / toxicity
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents / toxicity
  • Child
  • Humans
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Ribonucleosides / therapeutic use*
  • Ribonucleosides / toxicity*

Substances

  • Antineoplastic Agents
  • Ribonucleosides
  • Aminoimidazole Carboxamide
  • acadesine